Personal information

Other IDs

SciProfiles: 1303456

Countries

United States

Activities

Collapse all

Employment (2)

Foundation Medicine Inc: Cambridge, MA, US

2022-04-18 to present | Translational Scientist (Clinical Development)
Employment
Source: Self-asserted source
Julia C. F. Quintanilha

University of North Carolina: Chapel Hill, NC, US

2020-09-14 to 2022-03-30 | Postdoctoral Research Associate (Eshelman School of Pharmacy)
Employment
Source: Self-asserted source
Julia C. F. Quintanilha

Education and qualifications (3)

State University of Campinas: Campinas, SP, BR

2017-03-01 to 2020-09-03 | PhD in Medical Sciences
Qualification
Source: Self-asserted source
Julia C. F. Quintanilha

State University of Campinas: Campinas, SP, BR

2015-03-01 to 2017-02-07 | MSc in Medical Sciences
Education
Source: Self-asserted source
Julia C. F. Quintanilha

University of São Paulo: Ribeirão Preto, SP, BR

2009-03-09 to 2013-12-12 | Pharmacist
Education
Source: Self-asserted source
Julia C. F. Quintanilha

Funding (1)

Genetic modifiers of drug-induced hypertension for risk assessment of patients treated with VEGF-pathway inhibitors

2021-04-01 to 2022-03-31 | Grant
American Heart Association (Dallas, US)
GRANT_NUMBER:

826128
Source: check_circle
American Heart Association

Works (30)

Genomic alterations associated with early-stage disease and early recurrence in patients with colorectal cancer

The Oncologist
2025-02-06 | Journal article
DOI: 10.1093/oncolo/oyae269
Contributors: Leontios Pappas; Julia C F Quintanilha; Richard S P Huang; Aparna R Parikh
Source: check_circle
Crossref

Real‐world genomic landscape of colon and rectal cancer

FEBS Open Bio
2025-01-26 | Journal article
DOI: 10.1002/2211-5463.13957
Contributors: Markus Schulze; XiaoZhe Wang; Jawad Hamad; Julia C. F. Quintanilha; Lincoln W. Pasquina; Julia F. Hopkins; Juergen Scheuenpflug; Zheng Feng
Source: check_circle
Crossref

Data from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

2024-10-15 | Preprint
DOI: 10.1158/1078-0432.c.7493982
Contributors: Debra L. Richardson; Julia C. F. Quintanilha; Natalie Danziger; Gerald Li; Ethan Sokol; Alexa B. Schrock; Ericka Ebot; Neeru Bhardwaj; Tanesha Norris; Anosheh Afghahi et al.
Source: check_circle
Crossref

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

Clinical Cancer Research
2024-10-15 | Journal article
DOI: 10.1158/1078-0432.CCR-24-1225
Contributors: Debra L. Richardson; Julia C. F. Quintanilha; Natalie Danziger; Gerald Li; Ethan Sokol; Alexa B. Schrock; Ericka Ebot; Neeru Bhardwaj; Tanesha Norris; Anosheh Afghahi et al.
Source: check_circle
Crossref

Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

2024-10-15 | Preprint
DOI: 10.1158/1078-0432.27231165
Contributors: Debra L. Richardson; Julia C. F. Quintanilha; Natalie Danziger; Gerald Li; Ethan Sokol; Alexa B. Schrock; Ericka Ebot; Neeru Bhardwaj; Tanesha Norris; Anosheh Afghahi et al.
Source: check_circle
Crossref

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension

The Pharmacogenomics Journal
2024-08 | Journal article
DOI: 10.1038/s41397-024-00342-1
Contributors: Julia C. F. Quintanilha; William Kevin Kelly; Federico Innocenti
Source: check_circle
Crossref

Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data

ESMO Real World Data and Digital Oncology
2024-06 | Journal article
DOI: 10.1016/j.esmorw.2024.100036
Contributors: M.J. Emmett; J.C.F. Quintanilha; R.P. Graf; G. Li; H. Tukachinsky; A.B. Schrock; S. Morley; V.A. Fisher; G.R. Oxnard; C.H. Lieu et al.
Source: check_circle
Crossref

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

Clinical Cancer Research
2024-02-16 | Journal article
DOI: 10.1158/1078-0432.CCR-23-2693
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.c.7077717
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.c.7077717.v1
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232172
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232172.v1
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232169.v1
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232169
Contributors: Pashtoon M. Kasi; Jessica K. Lee; Lincoln W. Pasquina; Brennan Decker; Pierre Vanden Borre; Dean C. Pavlick; Justin M. Allen; Christine Parachoniak; Julia C. F. Quintanilha; Ryon P. Graf et al.
Source: check_circle
Crossref

Data Normalization of Urine miRNA Profiling from Head and Neck Cancer Patients Treated with Cisplatin

International Journal of Molecular Sciences
2023-06-29 | Journal article
DOI: 10.3390/ijms241310884
Contributors: Nadine de Godoy Torso; Julia Coelho França Quintanilha; Maria Aparecida Cursino; Eder de Carvalho Pincinato; Carmen Silvia Passos Lima; Patricia Moriel
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

Cells
2023-06-07 | Journal article
DOI: 10.3390/cells12121574
Contributors: George W. Small; Farida S. Akhtari; Adrian J. Green; Tammy M. Havener; Michael Sikes; Julia Quintanhila; Ricardo D. Gonzalez; David M. Reif; Alison A. Motsinger-Reif; Howard L. McLeod et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

MKX-AS1 Gene Expression Associated with Variation in Drug Response to Oxaliplatin and Clinical Outcomes in Colorectal Cancer Patients

Pharmaceuticals
2023-05-17 | Journal article
DOI: 10.3390/ph16050757
Contributors: Ricardo D. Gonzalez; George W. Small; Adrian J. Green; Farida S. Akhtari; Alison A. Motsinger-Reif; Julia C. F. Quintanilha; Tammy M. Havener; David M. Reif; Howard L. McLeod; Tim Wiltshire
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

RYK Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

Pharmaceuticals
2023-05-10 | Journal article
DOI: 10.3390/ph16050726
Contributors: Ricardo D. Gonzalez; George W. Small; Adrian J. Green; Farida S. Akhtari; Tammy M. Havener; Julia C. F. Quintanilha; Amber B. Cipriani; David M. Reif; Howard L. McLeod; Alison A. Motsinger-Reif et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer

The Oncologist
2023-03-17 | Journal article
DOI: 10.1093/oncolo/oyac265
Contributors: Julia C F Quintanilha; Ryon P Graf; Geoffrey R Oxnard
Source: check_circle
Crossref

KDR genetic predictor of toxicities induced by sorafenib and regorafenib

The Pharmacogenomics Journal
2022-12 | Journal article
DOI: 10.1038/s41397-022-00279-3
Contributors: Julia C. F. Quintanilha; Susan Geyer; Amy S. Etheridge; Alessandro Racioppi; Kelli Hammond; Daniel J. Crona; Carol E. Peña; Sawyer B. Jacobson; Federica Marmorino; Daniele Rossini et al.
Source: check_circle
Crossref

Plasma levels of VEGF‐A and VCAM‐1 as predictors of drug‐induced hypertension in patients treated with VEGF pathway inhibitors

British Journal of Clinical Pharmacology
2022-09 | Journal article
DOI: 10.1111/bcp.15356
Contributors: Julia C. F. Quintanilha; Kelli Hammond; Yingmiao Liu; Federica Marmorino; Beatrice Borelli; Chiara Cremolini; Andrew B. Nixon; Federico Innocenti
Source: check_circle
Crossref

Differentially expressed plasmatic microRNAs in Brazilian patients with Coronavirus disease 2019 (COVID-19): preliminary results

Molecular Biology Reports
2022-07 | Journal article
DOI: 10.1007/s11033-022-07338-9
Contributors: Aline de Souza Nicoletti; Marília Berlofa Visacri; Carla Regina da Silva Correa da Ronda; Pedro Eduardo do Nascimento Silva Vasconcelos; Julia Coelho França Quintanilha; Rafael Nogueira de Souza; Deise de Souza Ventura; Adriana Eguti; Lilian Ferreira de Souza Silva; Mauricio Wesley Perroud Junior et al.
Source: check_circle
Crossref

Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

The Pharmacogenomics Journal
2022-03 | Journal article
DOI: 10.1038/s41397-021-00264-2
Contributors: Julia C. F. Quintanilha; Alessandro Racioppi; Jin Wang; Amy S. Etheridge; Stefanie Denning; Carol E. Peña; Andrew D. Skol; Daniel J. Crona; Danyu Lin; Federico Innocenti
Source: check_circle
Crossref

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

The Pharmacogenomics Journal
2022-02 | Journal article
DOI: 10.1038/s41397-021-00261-5
Contributors: Julia C. F. Quintanilha; Alessandro Racioppi; Jin Wang; Amy S. Etheridge; Stefanie Denning; Carol E. Peña; Andrew D. Skol; Daniel J. Crona; Danyu Lin; Federico Innocenti
Source: check_circle
Crossref

Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens

International Journal of Cancer
2022-01-15 | Journal article
DOI: 10.1002/ijc.33810
Contributors: Julia C. F. Quintanilha; Jin Wang; Alexander B. Sibley; Wei Xu; Osvaldo Espin‐Garcia; Chen Jiang; Amy S. Etheridge; Mark J. Ratain; Heinz‐Josef Lenz; Monica Bertagnolli et al.
Source: check_circle
Crossref

MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer

2021-04-12 | Other
DOI: 10.21203/rs.3.rs-147058/v2
Contributors: Julia C.F. Quintanilha; Maria A. Cursino; Jessica B. Borges; Nadine G. Torso; Larissa B. Bastos; Juliana M. Oliveira; Thiago S. Cobaxo; Eder Pincinato; Mario H. Hirata; Murilo V. Geraldo et al.
Source: check_circle
Crossref

MicroRNAs como possíveis biomarcadores de nefrotoxicidade induzida pela cisplatina em pacientes com câncer de cabeça e pescoço

2019-11-30 | Conference paper
DOI: 10.20396/revpibic2720191900
Contributors: Thiago Cobaxo; Patricia Moriel; Julia Quintanilha; Maria Cursino; Pedro Vasconcelos; Larissa Bastos; Juliana Oliveira; Carmen Lima
Source: check_circle
Crossref

Possível relação dos polimorfismos no gene ABCB1 com as toxicidades induzidas por cisplatina em pacientes com câncer de cabeça e pescoço

2019-11-30 | Conference paper
DOI: 10.20396/revpibic2720191650
Contributors: Larissa Bastos; Patricia Moriel; Maria Cursino; Julia Quintanilha; Camila Oliveira; Nadine Torso; Marília Visacri; Rosario Hirata; Mario Hirata; Carmem Lima
Source: check_circle
Crossref

Role of epigenetic mechanisms in cisplatin-induced toxicity

Critical Reviews in Oncology/Hematology
2019-05 | Journal article
DOI: 10.1016/j.critrevonc.2019.03.004
Contributors: Júlia Coelho França Quintanilha; Kathleen Francinette Saavedra; Marília Berlofa Visacri; Patricia Moriel; Luis A. Salazar
Source: check_circle
Crossref

Brazil’s resolutions to regulate the sale of antibiotics: Impact on consumption and Escherichia coli resistance rates

Journal of Global Antimicrobial Resistance
2017-09 | Journal article
DOI: 10.1016/j.jgar.2017.05.023
Contributors: Karen P.H. Mattos; Marília B. Visacri; Júlia C.F. Quintanilha; Gustavo R. Lloret; Maria A. Cursino; Anna S. Levin; Carlos E. Levy; Patricia Moriel
Source: check_circle
Crossref
How many people are using ORCID?